Literature DB >> 32483585

Response to Brandt, Bednarz-Knoll, Kleinheinz et al.

Anil K Chaturvedi1, Natalia Udaltsova2, Eric A Engels1, Jed A Katzel2, Elizabeth L Yanik3, Hormuzd A Katki1, Mark W Lingen4, Michael J Silverberg5.   

Abstract

Year:  2020        PMID： 32483585      PMCID： PMC7492756          DOI： 10.1093/jnci/djaa075

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Teaching moment: why promising biomarkers do not always translate into clinically useful tests.

Authors:  Philip E Castle
Journal:  J Clin Oncol       Date:  2013-12-23       Impact factor: 44.544

2.  RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.

Authors:  Burkhard H Brandt; Natalia Bednarz-Knoll; Johannes Kleinheinz; Andre Franke; Thomas Fillies
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

Review 3.  From differences in means between cases and controls to risk stratification: a business plan for biomarker development.

Authors:  Nicolas Wentzensen; Sholom Wacholder
Journal:  Cancer Discov       Date:  2013-01-08       Impact factor: 39.397

Review 4.  Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis.

Authors:  Hisham M Mehanna; Tim Rattay; Joel Smith; Christopher C McConkey
Journal:  Head Neck       Date:  2009-12       Impact factor: 3.147

5.  Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

Authors:  William N William; Vassiliki Papadimitrakopoulou; J Jack Lee; Li Mao; Ezra E W Cohen; Heather Y Lin; Ann M Gillenwater; Jack W Martin; Mark W Lingen; Jay O Boyle; Dong M Shin; Nadarajah Vigneswaran; Nancy Shinn; John V Heymach; Ignacio I Wistuba; Ximing Tang; Edward S Kim; Pierre Saintigny; Elizabeth A Blair; Timothy Meiller; J Silvio Gutkind; Jeffrey Myers; Adel El-Naggar; Scott M Lippman
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.